Solid Biosciences Inc [SLDB] stock is trading at $5.78, down -3.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The SLDB shares have gain 46.70% over the last week, with a monthly amount glided 85.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Solid Biosciences Inc [NASDAQ: SLDB] stock has seen the most recent analyst activity on January 08, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $16. Previously, Wedbush started tracking the stock with Outperform rating on December 13, 2024, and set its price target to $16. On December 10, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $15 on the stock. JP Morgan upgraded its rating to a Overweight and increased its price target to $15 on July 15, 2024. Leerink Partners upgraded its rating to a Outperform but $12 remained the price target by the analyst firm on June 24, 2024. In a note dated March 28, 2024, William Blair initiated an Outperform rating and provided a target price of $40 on this stock.
Solid Biosciences Inc [SLDB] stock has fluctuated between $2.88 and $15.05 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Solid Biosciences Inc [NASDAQ: SLDB] shares were valued at $5.78 at the most recent close of the market. An investor can expect a potential return of 202.77% based on the average SLDB price forecast.
Analyzing the SLDB fundamentals
Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -23.67%, Pretax Profit Margin comes in at -21.63%, and Net Profit Margin reading is -21.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.59 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.47 points at the first support level, and at 5.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.12, and for the 2nd resistance point, it is at 6.46.
Ratios To Look Out For
For context, Solid Biosciences Inc’s Current Ratio is 7.85. On the other hand, the Quick Ratio is 7.85, and the Cash Ratio is 2.82.
Transactions by insiders
Recent insider trading involved Bain Capital Life Sciences Inv, 10% Owner, that happened on Feb 19 ’25 when 1.0 million shares were purchased. Director, PERCEPTIVE ADVISORS LLC completed a deal on Feb 19 ’25 to buy 5.0 million shares. Meanwhile, 10% Owner Adage Capital Management, L.P. bought 0.25 million shares on Feb 18 ’25.
